http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Satoshi Yamamura,Masaki Ikarashi,Masami Sasaki 한국응용곤충학회 2008 Journal of Asia-Pacific Entomology Vol.11 No.3
Information on the biology of the alpine moth, Syngrapha ottolenguii, is very limited. On the main island of Japan, Honshu, we determined a natural host plant of S. ottolenguii to be Empetrum nigrum in alpine fields; the larvae showed a characteristic nocturnal feeding behavior on this plant. During daytime, the moths hid in the lower layer of the dense E. nigrum shrub. S. ottolenguii exhibited a univoltine life cycle with hibernation at the second or third instar larval stage under deep snow, where the temperature stayed stable at 0 °C for about 6 months. They could be reared with a generation time of about 60 days on an artificial diet under 16L– 8D at 20 °C. The larva was classified as a monosetose with subventral (SV) setae on the second and third thoracic segments. Information on the biology of the alpine moth, Syngrapha ottolenguii, is very limited. On the main island of Japan, Honshu, we determined a natural host plant of S. ottolenguii to be Empetrum nigrum in alpine fields; the larvae showed a characteristic nocturnal feeding behavior on this plant. During daytime, the moths hid in the lower layer of the dense E. nigrum shrub. S. ottolenguii exhibited a univoltine life cycle with hibernation at the second or third instar larval stage under deep snow, where the temperature stayed stable at 0 °C for about 6 months. They could be reared with a generation time of about 60 days on an artificial diet under 16L– 8D at 20 °C. The larva was classified as a monosetose with subventral (SV) setae on the second and third thoracic segments.
MASUNO, Koichi,FUKUDA, Yasuhiro,KUBO, Masahito,IKARASHI, Ryo,KURAISHI, Takeshi,HATTORI, Shosaku,KIMURA, Junpei,KAI, Chieko,YANAI, Tokuma,NAKAI, Yutaka The Japanese Society of Veterinary Science 2014 The Journal of veterinary medical science Vol.76 No.2
<P><B>ABSTRACT</B></P><P><I>Cryptosporidium andersoni</I> and <I>Cryptosporidium muris</I> infections have been found in the mice and/or cattle. The oocysts of <I>C. andersoni</I> and <I>C. muris</I> have been sporadically detected in human feces, but the infectious capacity and features have been unknown, because of the scarcity of reports involving human infections. To assess the infectivity and the clinical and pathological features of <I>C. andersoni</I> and <I>C. muris</I> in primates, an experimental infectious study was conducted using cynomolgus monkeys. The monkeys were orally inoculated with oocysts of two different <I>C. andersoni</I> Kawatabi types and <I>C. muris</I> RN-66 under normal and immunosuppressive conditions. The feces of the monkeys were monitored for about 40 days after the administration of oocysts using the flotation method, but no shedding oocysts were observed under either both normal or immunosuppressive conditions. Gross and histopathological examinations were performed on the immunosuppressive monkeys, but these revealed no evidence of <I>Cryptosporidium</I> infections, even though the monkeys were subjected to immunosuppressive conditions. It is hypothesized that <I>C. andersoni</I> and <I>C. muris</I> pose little danger of infection in primates even under immunosuppressive conditions.</P>
( Miki Koroku ),( Teppei Omori ),( Harutaka Kambayashi ),( Shun Murasugi ),( Tomoko Kuriyama ),( Yuichi Ikarashi ),( Maria Yonezawa ),( Ken Arimura ),( Kazunori Karasawa ),( Norio Hanafusa ),( Masatos 대한장연구학회 2022 Intestinal Research Vol.20 No.1
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19. (Intest Res 2022;20:150-155)